Author

Nabil Georges Seidah

Montreal Clinical Research InstituteORCID 0000-0001-6503-9342Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Molecular Biology· 2 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 3 Research Focus:host-pathogen & immune response· 1 Assay:protein structure· 1 Research Focus:protein structure prediction· 1 Assay:proteomics· 1

Frequent Co-Authors

Alexandra EvagelidisiD· 1 shared Ali Ben Djoudi Ouadda· 1 shared Amy Madeleine Kempf· 1 shared Andrew R. Reynolds· 1 shared Anke WerneriD· 1 shared Annik PratiD· 1 shared Anthoula LazarisiD· 1 shared Aurélien ThureauiD· 1 shared

Activity by Year

2022-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 17 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperMolecular Biology

Alexandra EvagelidisORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Proteolytic processing of the Marburg virus glycoprotein depends on Sec616β and is required for cell entry

Katharina E. Decker, Anke Werner, Markus Hoffmann, Heike Hofmann-Winkler, Qi-Yin Chen, Lu Zhang, Pamela Stomberg, Sabine Gärtner, Amy Madeleine Kempf, Inga Nehlmeier, Hendrik Luesch, Torsten Steinmetzer, Eva Böttcher‐Friebertshäuser, Nabil Georges Seidah, Stefan Pöhlmann, Michael Winkler

This paper identifies Sec61β as essential for proteolytic processing and cell entry of Marburg virus glycoprotein, unlike Ebola virus, and suggests Sec61 as a therapeutic target.

bioRxiv · Jun 26, 2025 · PreprintMicrobiology

Inhibition of proprotein convertase subtilisin-like kexin type 9 (PCSK9) potentiates anti-angiogenic therapy in colorectal cancer liver metastases

Miran Rada, Andrew R. Reynolds, Anthoula Lazaris, Nabil Georges Seidah, Peter P. Metrakos

This study shows that PCSK9 inhibition enhances anti-angiogenic therapy effectiveness in colorectal cancer liver metastases with vessel co-option.

bioRxiv · May 29, 2023 · PreprintMolecular Biology

Molecular interactions of PCSK9 with an inhibitory nanobody, CAP1 and HLA-C: functional regulation of LDLR levels

Carole Fruchart‐Gaillard, Ali Ben Djoudi Ouadda, Lidia Ciccone, Emmanuelle Girard, Sepideh Mikaeeli, Alexandra Evagelidis, Maïlys Le Dévéhat, Delia Susan‐Resiga, Evelyne Cassar Lajeunesse, Hervé Nozach, Oscar Henrique Pereira Ramos, Aurélien Thureau, Pierre Legrand, Annik Prat, Vincent Dive, Nabil Georges Seidah

This study determines the 3D structure of the PCSK9-CHRD-P1.40 complex and shows how CAP1 and HLA-C interact with PCSK9 to regulate LDLR degradation.

Molecular Metabolism · Dec 22, 2022Peer-reviewedMolecular Biology